Breast cancer results in approximately 670,000 fatalities each year. According to data from the World Health Organization (WHO), breast cancer was the most prevalent cancer among women in 157 out of 185 countries in 2022. Over 2 million women receive a breast cancer diagnosis annually. Detecting this lethal disease early and developing a drug that targets cancer cells is crucial. The US Food and Drug Administration (FDA) has granted approval for Kisqali to be used in the treatment of early-stage breast cancer. Also known as ribociclib, this medication has been approved for use in conjunction with hormone therapy for early-stage breast cancer patients who are concerned about cancer recurrence. The FDA officially stated that Kisqali (ribociclib) has been approved, in combination with an aromatase inhibitor, for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Additionally, the FDA approved the ribociclib and letrozole co-pack (Kisqali Femara Co-Pack) for the same purpose. Kisqali is classified as a selective cyclin-dependent kinase inhibitor, a type of drug that helps slow cancer progression by inhibiting cyclin-dependent kinase 4 and 6 (CDK4/6) proteins, according to Novartis, the manufacturer. Overactive CDK4/6 proteins can promote rapid growth and division of cancer cells. By precisely targeting CDK4/6, Kisqali may prevent cancer cells from uncontrollably replicating. Kisqali is administered orally in pill form. The recommended dosage is 400 mg daily for three weeks followed by a one-week break, to be continued for three years. It can be taken with or without food.ed. Kisqali: Adverse effects

The typical adverse effects linked to Kisqali medication include reduced white blood cell count or neutropenia. Neutropenia happens when there is a decrease in neutrophil levels in the blood; neutrophils are crucial for combating infections in the body. Another potential side effect of Kisqali is liver problems and interstitial lung disease/pneumonitis. Breast Cancer: Warning signs of the disease that should not be overlooked.